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Introduction
One of the main challenges for population health in the developed world is the steady increase in obesity. In the US, in [2009] [2010] 35 .7 per cent of the adult population was obese (Ogden et al., 2012) , and in several European countries such as Spain and Germany, the corresponding percentages lay between 14.7 and 23 per cent. (Brunello et al., 2009; Mensink et al., 2013) .
The reasons for this trend are a combination of increased intake of calories and reduced physical activity (Finkelstein et al., 2005) and the resulting energy imbalance not only leads to a continuous weight gain but also to severe chronic conditions such as type 2 diabetes.
Globally, it is estimated that 438 million people (7.8% of the adult population) will have developed type 2 diabetes by 2030 unless effective prevention programs are implemented (International Diabetes Federation, 2009 ). Diabetes and other diseases emerging as consequences of excessive weight will also cause a sizable economic burden (Guh et al., 2009 ) through direct medical costs of treatment as well as indirect costs of illness such as disability and early retirement (Konnopka et al., 2009; Finkelstein et al., 2003) .
In response to this growing burden of obesity, public primary prevention programs against obesity have been widely recommended (WHO 2004) . The European guideline for the prevention of type 2 diabetes focuses on obesity and sedentary lifestyle as these are the main modifiable risk factors of the disease (Paulweber et al., 2010) . Several studies (Lindgren et al., 2007; DPP Research Group 2003; Icks et al., 2007; Bertram et al., 2010) estimated the cost effects of diabetes prevention trials for different countries. The studies differ with regard to intervention, population, time-perspective, measurement of the costs but they all find that diabetes prevention can be cost-effective (see reviews by Paulweber et al. 2010 and Klein et al., 2011) . Furthermore, Li et al., 2010 found that among all different interventions recommended by the American Diabetes Association (ADA), evidence was strongest for the cost-effectiveness of intensive lifestyle modification among persons with impaired glucose tolerance (IGT). Nevertheless, it is still controversial if prevention conducted in more realworld settings and among people with increased risk but not yet exhibiting IGT can really be a cost-effective strategy to cope with the obesity epidemic. We examine this question in a simulation model based on the results of the M.O.B.I.L.I.S program, a German lifestyle intervention to reduce obesity, which is directed on the high-risk group of people who are already obese. The contribution of this paper is the use of a Markov model to measure longterm benefits of this intervention due to prevention of type-2 diabetes. This paper is organized as follows. Section 2 is devoted to a description of data and methods and first presents an overview of the M.O.B.I.L.I.S. intervention and the analyzed data, followed by a characterization of the Markov model framework and the cost-benefit analysis.
Section 3 presents the results of the medium-term simulation and some sensitivity analyses. In Section 4 we discuss our findings. Concluding remarks are offered in Section 5. The effectiveness of the intervention in reducing weight and enhancing physical activity of the participants over the intervention period has been documented in the studies by Lagerstörm et al. (2013) and Berg et al. (2008) . Frey et al. (2010) also show that the intervention effects are persistent one year after program termination. Compared to the initial levels average weight was reduced by 6.8 kg (± 7.8) and weekly physical activity was significantly higher. Besides that, Göhner et al. (2012) find that compared to a quasiexperimental control group the participants show significantly enhanced psychological variables (self-efficacy, strength of goal intention) at a two-year follow-up.
Data and Methods

Overview
Year Follow-up
The were raised on a questionnaire basis.
[Insert Table 1] The descriptive statistics in Table 1 provide an overview of the sample characteristics before and after the intervention, as well as for the 4-year follow-up. The obesity measures (BMI, Waist-to-Hip ratio (WHR)) and reported physical activity have a common pattern over time.
Compared to the baseline, the intervention still has a positive effect at the follow-up, though there is a clear rebound effect when we regard the development after completion of the program. Looking at the other medical risk indicators, the interpretation is not as clear. For blood pressure, LDL cholesterol and fasting blood sugar the initial improvements after the intervention vanish, as the follow-up levels meet the baseline values. HDL cholesterol and HbA1c show a rising time trend, which might be due to general age effects (Davidson et al., 2010) overlapping possible intervention effects.
In order to check for possible self-selection effects in the follow-up sample we compare the responders to the non-responders with respect to their initial weight loss during the program.
The differences are not very strong, though we cannot exclude a self-selection bias for participation at the study. Among responders, 61.4 per cent had experienced a weight loss of more than 5% during program participation, whereas the respective number among the nonresponders was only 49.9 per cent, see Figure 1 for details. The response rate of those with an initial weight loss of less than 5% was 35.7 per cent, compared to 46.9 per cent for those who lost more than 5% during the program.
[Insert Figure 1 ]
Control Group
For an informative evaluation of the economic benefits of the intervention, based on the development of the risk factors we need to account for the general age-related trend in the population, which is achieved by including a control group. Due to the real-world implementation of the M.O.B.I.L.I.S. program and the retrospective study design, we are lacking an original randomized control group. We overcome this problem with the aid of an artificial control group, formed from a subgroup of N 0 =1308 individuals of the German socioeconomic panel (SOEP) who meet the same inclusion criteria at the beginning of the intervention. The SOEP sample (Wagner et al., 2007) is representative for the German population so that comparability for socio-economic and other background variables should be reasonably high. We performed propensity score matching estimated on the baseline covariates BMI, age and gender for the 2-nearest neighbors in the SOEP sample to build our artificial control group. The SOEP dataset only contains information on weight and BMI as diabetes risk factors, so we lose the information on the additional risk indicators in the M.O.B.I.L.I.S. dataset in the control group. As data on weight is available in the SOEP sample only every two years, we compute the annual BMI development to account for the one-year period of the intervention.
The average development in the matched control group in comparison to the measured intervention group values can be found in the first column of Table 2 . Being matched on the baseline BMI the control group shows no significant change in BMI in the period until completion of the program. Over the 4 years of the follow-up period the average BMI in the control group grows at a low rate from 34.458 to 35.088 kg/m 2 , and compared to the baseline value of 34.887 kg/m 2 the overall rise in weight of the control group is not significantly different from zero. Thus the average BMI in the control group is more or less constant over the observed period, while the intervention group shows the pattern of initial weight loss and a rebound in the following 4 years as described before.
[Insert Table 2] The observed BMI reduction from the start to the end of the intervention is 7.37 per cent, while the estimated average treatment effect (ATE) of BMI development is a 5.87 per cent reduction for the intervention group, compared to the control group. In the period between completion and 4-year follow-up the observed BMI in the intervention group grows by 4.60 per cent, whereas the ATE in this period only shows a 2.75 per cent rise in BMI for the intervention group. As the ATE is significantly below the observed rebound effect in the intervention group, we can state that weight regain effects of the intervention group at the follow-up are on average lower when we take the representative control into account. The differences in distribution over the three obesity subgroups overweight, obese and severely obese (BMI<30, 30≤BMI≤35, BMI>35) in the M.O.B.I.L.I.S. population and the control group are presented in Table 2 . All statistical analyses were performed using Stata 12.
Simulation framework
Evaluating Table 3 for an overview). Both groups enter the model at stage zero according to the observed (estimated) distributions over the model states at the 1-year follow-up. The five Markov states are: 1) no diagnosed diabetes and BMI < 30, 2) no diagnosed diabetes and 30 < BMI < 35, 3) no diagnosed diabetes and BMI > 35 (afterwards we will refer to these states as "non-diabetes"), 4) diagnosed diabetes and 5) the absorbing Markov state death. The initial age of the individuals entering the Markov model is 54 years, which is consistent with the average age at the follow-up in both groups.
With respect to the gender shares we simulate the model according to the mixed composition in the follow-up sample and in a separate subgroup analysis for females only. We do not run a separate subgroup for males, as the low number of male participants makes a sound analysis impossible.
[Insert Table 3 Due to missing data the transition from non-diabetes to death does not differ by BMI category. All people who die remain in this state forever and we only regard diagnosed cases of type-2 diabetes mellitus where no cure is feasible. Those probabilities are assumed to be equal for the two groups of individuals but they vary by age and are adjusted to the gender composition of the groups.
All simulations were performed using TreeAge Pro Healthcare (Release 1.0 b1, 2001;
TreeAge Software Inc.).
Cost-benefit analysis
The results of the Markov simulation are the foundation of the subsequent cost-benefit analysis. The analysis adopts the perspective of the health insurance system and abstracts from effects on human capital, work loss etc. Also, subjective utility from the health state does not enter the cost-benefit analysis. We measure the direct costs of diabetes by monetizing the simulation outcomes for diabetes prevalence in each year and in both groups. were compounded at an annual discount rate r of 3 per cent.
Sensitivity analyses
To check for the validity of our results we conducted one-way sensitivity analyses regarding the values of all parameters of the model.
Results
Mortality
The simulated cumulative annual mortalities depicted in Figure 3 , for the mixed gender groups, indicate that the intervention has no significant effect on the longevity of the individuals. The overall time trend of the mortality rates is the same for intervention group and control group, with the annual rates differing only at insignificantly low margins. The cumulative mortality after 20 years is 27.00% in the control group compared to 27.28% in the intervention group. The difference in average annual mortality rates between 1.35% in the control group and 1.36% in the intervention group is not significantly different from zero, either. The simulation results for the female subgroup show that the described mortality effects are independent of the gender composition of the groups. In this case the cumulative mortality rate after 20 years is 20.26% (20.05%) in the intervention (control) group.
Summarizing the results we can state that, at least in our model setup, the M.O.B.I.L.I.S.
intervention has no effects on long-term mortality rates.
[Insert Figure 3 ]
Diabetes prevalence
The annual prevalence rates of diabetes over the 20 years of the simulated time horizon are depicted for the intervention group and the control group in [Insert Figure 4 ]
The diabetes prevalence for the female subgroup shows the same pattern as described above for the mixed group, though the differences in prevalence rates are a bit less pronounced. On average the annual prevalence rate is 3.67% (5.10%) in the intervention (control) group. At the end of the simulated time horizon the diabetes prevalence is 8.04% in the intervention group compared to 10.97% in the control group. This prevalence being 26.7% lower in the intervention group compared to 31.9% in total indicates that the male share of the mixed sample has a positive influence on the effectiveness of the intervention as a whole.
Based on the diabetes prevalence projections we can make a first statement on the 
Cost-benefit Analysis
As discussed in the methods part, the results of the cost-benefit analysis depend on the average time between the onset of type 2 diabetes and the onset of complications (see Table 4 for an overview). In the extreme case of no complications at all, the M.O.B.I.L.I.S.
intervention does not pay off from the perspective of a sickness fund. In that situation with annual type-2 diabetes costs of 850 € the difference in the discounted diabetes costs between control and intervention group amounts to 446 €. With average intervention costs of 673 € for a sickness fund this leads to a negative net-benefit of 227 € for the mixed group and 269 € for the female subgroup.
[Insert Table 4] Following the rationale of the computation described in the methods part -with an average time till the onset of complications of 10 years -the M.O.B.I.L.I.S. intervention has a positive net-benefit. Based on the assumption that the costs of type-2 diabetes rise linearly from 850 € (cost without complications) in the first 5 years after diagnosis to 3057 € (25% complications on average) in year 10 and afterwards, the differences in diabetes cost are as follows. The discounted diabetes costs cumulated over the whole period of 20 years are 1000 € lower for individuals form the intervention group than for those from the control group. For the mixed gender group this results in a positive net-benefit of 327 € from the perspective of a sickness fund. The positive result also holds for the female subgroup, with a net-benefit of 299 €.
Sensitivity Analyses
The analysis in the previous section shows that the results of the CBA are affected by the Assuming an adjustment of the BMI development in the intervention group to the trend in the control group should be considered critical, as it influences our results considerably. Without this adjustment, the CBA results change significantly. The resulting net-benefit of the intervention drops to 129.7 €, compared to 327 € under the above assumption for the mixed group. The similar effect can be observed in the female subgroup were the net benefit drops from 299 € to 124.8 € without the adjustment assumption.
Discussion
We are well aware of the limitations and shortcomings of the current study that have to be considered. The first point to look at is the lack of a randomized control group for the evaluation. Although we are missing socioeconomic background variables for the intervention group to compare them directly with our matched control group, differences with respect to socioeconomic status should be a minor problem as the intervention group was recruited all over Germany and the control group is a matched representative subsample of the German population. The main problem of the artificial control group is, of course, that we cannot account for a possible selection bias with respect to participation in the intervention for the control group. This might exaggerate the effects for the intervention group -as participants have the intention to lose weight -but this will not alter the implications of the analysis for the evaluation of public prevention programs. As long as prevention programs offered by sickness funds are voluntary we will always observe comparable self-selection of participants.
Besides this selection effect at the baseline, we have to consider the differences between responders and non-responders at the 4 year follow-up, as mentioned in the data section and depicted in Figure Regarding the structure of the Markov model two points can be criticized, the pure foundation on BMI changes and the focus on diabetes as the only cost relevant outcome. We think the former issue is justified by the fact that our control group dataset does not allow for a richer model, as the BMI is the only relevant risk factor we can observe. The focus on the cost of diabetes might understate the effectiveness of the intervention in the CBA as we omit possible benefits due to other obesity associated diseases. Consequently we regard our positive netbenefit results as a lower benchmark for the effectiveness of the M.O.B.I.L.I.S. intervention and think that considering further diseases should add further benefits. The effect on the simulated mortality should on the other hand be minimal, as the overall mortality rates for obese persons used in the model as transition probabilities reflect the other diseases as well.
Conducting the CBA from the perspective of the health care system might neglect some additional benefits for the society at large. Nevertheless we think the health care system perspective is the right one for this analysis as we evaluate a program advertised and reimbursed by sickness funds. Besides looking at the simulation results we think there is another point for our perspective. As projected mortality rates in the intervention group and control group do not differ significantly, taking those effects into account would not change the CBA results we found form the perspective of the health care system. A further issue is that our analysis neglects sick leave costs of diabetes. This is a valid point, although in our model framework these costs -for a population with a starting age of 54 and a time horizon of 20 years -could only occur in the first years.
The difference in the magnitude of effects in the CBA between the mixed group and the female subgroup basically reflects the lower diabetes prevalence over the whole simulation horizon of women. On the other hand this effect is decreased by the higher female life expectancy. In combination with effects due to the composition of the mixed group we cannot make any predictions on the effectiveness for a subgroup of male participants.
Conclusion
In this paper we have shown that from the perspective of the health care system, real-world diabetes prevention programs for obese people such as the M.O.B.I.L.I.S. intervention may pay for themselves in the long run. We consider the net-benefit values of our study as a lower bound for the effectiveness of the intervention as we only evaluate the costs of diabetes.
Taking avoided costs of further obesity related diseases into account would presumably raise the benefits of the intervention. On the other hand, the estimated benefits themselves may be slightly biased upward due to the (mild) self-selection of participants. It seems, however, reasonable to assume that this upward bias is smaller than the downward bias mentioned before. From a policy point of view the results indicate that allowing sickness funds to invest in prevention might help to reduce health care expenditures, if the funds are able to detect effective programs and address the appropriate target groups. 
